No Data
No Data
CHAMPIONSCI(02509) rose 6.97%. Together with huadong medicine, they are conducting clinical and non-clinical research and registration related work on the target product QX005N.
Jingu Finance News | Quanxin Biotechnology (02509) rose more than 8% intraday, and as of press time, it rose 6.97%, to HKD 21.5, with a turnover of HKD 1.86 million. On the news front, the company announced that on July 19, 2024, it had entered into a cooperation agreement with huadong medicine's (000963) wholly-owned subsidiary, Zhongmei Huadong, on the co-development of clinical and non-clinical studies and registration related work for the symbol product QX005N. The announcement stated that if Zhongmei Huadong exercises its option, it will be responsible for the marketing and promotion of the symbol product in the authorized region, while the company will be responsible for the supply and quality of the symbol product and clinical trial samples.
Hong Kong stocks have changed | Qunxin Biotech-B (02509) rose more than 3% and reached a strategic cooperation agreement with Huadong Medicine on QX005N injection.
Quanxin Biotech-B (02509) rose more than 3%, as of press time, up 3.48%, and reported 20.8 Hong Kong dollars, with a turnover of 1.0786 million Hong Kong dollars.
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug
Quansheng Biotech-B (02509) has entered into a cooperation agreement with China-America East for the development and potential commercialization of QX005N.
Quanxin Biology-B (02509) announced that on July 19, 2024, the company reached a strategic cooperation with huadong medicine (its shares...
Returns On Capital At Huadong Medicine (SZSE:000963) Paint A Concerning Picture
No Data